With a median follow - up of 14 months, patients assigned to combination treatment
with cobimetinib and vemurafenib had a progression - free survival of 12.3 months compared with 7.2 months for those on vemurafenib alone.
The most common adverse events seen
with cobimetinib / vemurafenib were diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting.
Not exact matches
We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before entering into partnerships
with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally.
The US Food and Drug Administration (FDA) has approved the MEK inhibitor
cobimetinib (Cotellic) in combination
with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF - mutated melanoma.